Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: A phase II study

World Journal of Gastroenterology

Volumn 13, Issue 48, 2007, Pages 6553-6557

  Di Lorenzo, Giuseppe ^a   Rea, Antonio ^b   Carlomagno, Chiara ^a   Pepe, Stefano ^a   Palmieri, Giovannella ^a   Labianca, Roberto ^d   Chirianni, Antonio ^c   De Stefano, Alfonso ^a   Esposito, Vincenzo ^c   De Placido, Sabino ^a   Montesarchio, Vincenzo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AO Dei Colli Hospital for Infectious Diseases D Cotugno   (Italy)

^c Divisione di Malattie Infettive Azienda Ospedaliera   (Italy)

^d OSPEDALI RIUNITI   (Italy)

Author keywords

5 fluorouracil; Folinic acid; Hepatocellular carcinoma; Pegylated liposomal doxorubicin

Indexed keywords

ANTIEMETIC AGENT; DOXORUBICIN; FLUOROURACIL; FOLAREN; FOLINIC ACID; HEMOPOIETIC GROWTH FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 38349018498     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.13.6553     Document Type: Article

References (29)

1. La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000; 36: 909-915
2. Llovet JM, Bruix J, Gores GJ. Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: 1019-1021
3. Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 2006; 33: S79-S83
4. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105: 65-75
5. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988; 62: 479-483
6. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8: 117-136
7. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54 Suppl 4: 15-21
8. Ruff P, Moodley SD, Rapaport DA. Long term follow-up of pegylated liposomal doxorubicin: a well tolerated and effective agent in advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2001; 20: Abstract: 667
9. Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC. Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 2001; 85: 1850-1852
10. Hong RL, Tseng YL. A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003; 51: 433-438
11. Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: S319-S328
12. Hofheinz RD, Willer A, Weisser A, Gnad U, Saussele S, Kreil S, Hartmann JT, Hehlmann R, Hochhaus A. Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. Br J Cancer 2004; 90: 1893-1897
13. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10
14. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430
15. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 2004; 40: 1474-1484
16. Chou YY, Cheng AL, Hsu HC. Expression of P-glycoprotein and p53 in advanced hepatocellular carcinoma treated by single agent chemotherapy: clinical correlation. J Gastroenterol Hepatol 1997; 12: 569-575
17. Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5: 1676-1681
18. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1777-1785
19. Halm U, Etzrodt G, Schiefke I, Schmidt F, Witzigmann H, Mossner J, Berr F. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. Ann Oncol 2000; 11: 113-114
20. Miller RL, Bowen KE, Chung HG. A phase II study of liposomal doxorubicin in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002; 21: Abstract: 2324
21. Valle JW, Dangoor A, Beech J, Sherlock DJ, Lee SM, Scarffe JH, Swindell R, Ranson M. Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. Br J Cancer 2005; 92: 628-630
22. Poh SB, Bai LY, Chen PM. Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. Am J Clin Oncol 2005; 28: 540-546
23. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taieb J. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109: 1384-1390
24. Park SH, Lee Y, Han SH, Kwon SY, Kwon OS, Kim SS, Kim JH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer 2006; 6: 3
25. Chao Y, Chan WK, Birkhofer MJ, Hu OY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY, Lee SD. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998; 78: 34-39
26. O'Reilly EM, Stuart KE, Sanz-Altamira PM, Schwartz GK, Steger CM, Raeburn L, Kemeny NE, Kelsen DP, Saltz LB. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001; 91: 101-105
27. Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, Misset JL, Goldwasser F. Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 2002; 25: 198-203
28. Llovet J, Ricci S, Mazzaferro V. Sorafenib improves survival in advanced Hepatocellular Cancer. A randomized placebo-controlled trial (SHARP Trial). Proc Am Soc Clin Oncol Chicago 2007, Plenary Session; Abstract: LBA1
29. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-2380